Monocyte IL-2Ra expression is associated with thrombosis and Jak2V617F mutation in myeloproliferative meoplasms

GOETTE NORA P; LEV PAOLA R; HELLER PAULA G; KORNBLIHTT LAURA I; KORIN LAURA; MOLINAS FELISA C; MARTA ROSANA F

CYTOKINE.

ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD

Lugar: Amsterdam; Año: 2010 vol. 51 p. 67 - 72

1043-4666

The development of bone marrow fibrosis and thrombosis are main causes of morbidity in essential thrombocythemia (ET). Monocyte activation has been associated to the production of fibrosis-related cytokines and pro-thrombotic factors. The aim of this study was to identify new markers of monocyte activation in Phi-negative myeloproliferative neoplasms and to search for their relationship with clinical features. Forty-five patients comprising 30 ET, eight myelofibrosis and seven polycythemia vera were included. We evaluated the a subunit of IL-2 receptor (CD25) on monocytes, basal and LPS-induced IL-1b release from mononuclear cells, and monocyte TGF-b mRNA content. Patients who had thrombotic events displayed higher monocyte CD25 levels (6.2%) than those without symptoms (1.3%) and controls (2.6%), p = 0.0006. JAK2V617F-positive patients had higher monocyte CD25 expression levels (4.7%), than JAK2V617F-negative (2.6%), p = 0.0213. Patients with myeloproliferative neoplasms had similar monocyte CD25 expression than controls, both, in basal conditions and after cell adhesion. IL-1b release and TGF-b mRNA levels were normal. In conclusion, increased monocyte CD25 expression is associated with history of thrombosis and is also up-regulated in patients harboring JAK2V617F mutation. The finding of increased CD25 levels together with normal IL-1b and TGF-b production reveals a selective monocyte activation profile in myeloproliferative neoplasms.